Preclinical evidence of KRAS-mutant colorectal cancer shows that targeted inhibition of mitogen-activated protein kinase (MAPK) (MEK) deeply blocks the naive priming of CD8 (+) T cells in tumor-bearing mice and increases their number inside. The gene discussed is MAP2K7; the disease is neoplasm.